Arkion Life Sciences Announces Promotions

NEW CASTLE, DE, Aug. 13, 2025 – Arkion Life Sciences announced today the promotion of two executives in its EgCel® IgY Technology business unit.

Shawn W. Jones, PhD, has been promoted to Director of Innovation & Manufacturing, EgCel IgY Technology and Michelle Tollefson has been promoted to Director of Commercialization, EgCel IgY Technology. Both are key executives within the business unit and will drive adoption and growth of the EgCel portfolio of products (EggTek® and ActivEgg®), pipeline innovations and new services brought to market.

EgCel IgY products provide a blanket of specific IgY antibodies to help close “the gap” between passive immunity provided by colostrum and the animal’s active immunity provided by vaccines.

Jones is a published researcher and microbiologist who oversees production, research and development on the EgCel line of immune support products. He joined Arkion in 2020 and was most recently the Process and Development Manager. Prior to coming to Arkion, he worked to develop and scale-up novel fermentation and microbial processes for biomaterials and nutrition products.

Tollefson, former Business Director for EgCel IgY, joined Arkion in 2021. In her new role, she will bring new products and services to market and ensure their commercial success. Prior to Arkion, she held senior brand and marketing roles at Elanco, Bayer Animal Health, Boehringer Ingelheim, and Pfizer, with a track record of delivering growth across dairy, swine, poultry, and pet health segments.

Both promotions are effective immediately.

About Arkion Life Sciences
Arkion Life Sciences is dedicated to delivering products that meet the highest standards of quality and efficacy. EgCel® IgY Technology products align with the company’s mission to provide innovative natural solutions for improving health and wellness. For more information about EgCel IgY Technology products, please visit www.arkionls.com.

Media Contact
Keena Lykins
312.799.0106 (m)
klykins@mac.com